The Group reported revenue growth of 7% (6% in constant currency) to $3.349 billion, compared to $3.127 billion in 2024 with growth in all three geographies, North America, MENA, and Europe. At the same time, we are successfully transforming our Hikma Rx business, adding resilience and exciting new growth opportunities that will enable us to maintain attractive margins. While the search is ongoing, Areb Kurdi, currently VP, Group Financial Controller, will become Acting CFOHafrun Fridriksdottir, currently President, Hikma Rx, will become President, US. Hikma Rx reported revenue grew 1%. We expect Hikma Rx revenue to be broadly flat.

Source: GNN Liberia February 26, 2026 11:05 UTC